Hutchmed returns to revenue growth in first half of 2026
Drugmaker Hutchmed (China) Ltd. (HCM.US; 0013.HK) on Thursday reported its revenue rose slightly in the first half of 2026, as double-digit growth for its core portfolio of cancer and immunology…
Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
China’s biggest supplier of temperature-controlled services for the drug sector has renewed a Hong Kong listing plan, raising questions with hefty pre-IPO payouts Key Takeaways: Turnover has grown steadily, driven…
Legend Bio CEO resigns, shares tumble
Drugmaker Legend Biotech Corp. (LEGN.US) said on Monday that Huang Ying resigned as the company’s CEO and member of its board effective July 24, without giving any reason for his departure.…
Jiangxi Bio launches $60 million IPO, warns of sharp profit decline this year
Human tetanus antitoxin (TAT) maker Jiangxi Institute of Biological Products Inc. (6915.HK) launched its Hong Kong IPO on Monday, offering 36.23 million shares for HK$13.06 each to raise HK$473 million…
WuXi AppTec sues to get its name removed from U.S. blacklist
Pharmaceutical services provider WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) has sued the U.S. Defense Department, seeking to have its name removed from the department’s list of Chinese companies with military…
BRIEF: Heavily oversubscribed TenNor Therapeutics soars in trading debut
Shares of Biotechnology firm TenNor Therapeutics (Suzhou) Ltd. (6872.HK) nearly tripled in their Hong Kong debut on Friday, doubling when trading began and rising throughout the day to close at HK$211, up 179%.…
BRIEF: Zai Lab revenue falls on fading sales for its best-selling drug
Drug developer Zai Lab Ltd. (ZLB.US; 9688.HK) on Thursday reported its revenue fell 6% to $99.6 million in the first quarter from $106.5 million a year earlier, blaming a big…
Recent Articles
Hutchmed returns to revenue growth in first half of 2026
HCM.US
0013.HK
WuXi AppTec sues to get its name removed from U.S. blacklist
2359.HK
603259.SHG
RELATED ARTICLES
-
BRIEF: Hutchmed’s revenue drops 13% in 2025
HCM.US0013.HK
- Niu Technologies charges into 2026 with big growth targets
-
Texhong spins 75% profit growth in first half of 2026
2678.HK
-
Harbin Electric records strong profit growth in first half of 2026
1133.HK
-
Dtech profit rises fourfold in first half of 2026
1377.HK301377.SHE
-
CR Land’s sales rise 5% in first half of 2026 despite property downturn
1109.HK
-
BRIEF: iQiyi returns to revenue growth on big gains for content distribution business
IQ.US
